PL3600315T3 - Nowe terapeutyczne zastosowanie ligandów h3 - Google Patents

Nowe terapeutyczne zastosowanie ligandów h3

Info

Publication number
PL3600315T3
PL3600315T3 PL18714194.0T PL18714194T PL3600315T3 PL 3600315 T3 PL3600315 T3 PL 3600315T3 PL 18714194 T PL18714194 T PL 18714194T PL 3600315 T3 PL3600315 T3 PL 3600315T3
Authority
PL
Poland
Prior art keywords
ligands
therapeutical use
new therapeutical
new
therapeutical
Prior art date
Application number
PL18714194.0T
Other languages
English (en)
Polish (pl)
Inventor
Jeanne-Marie Lecomte
Jean-Charles Schwartz
Olivier Labeeuw
Marc Capet
Original Assignee
Bioprojet Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioprojet Pharma filed Critical Bioprojet Pharma
Publication of PL3600315T3 publication Critical patent/PL3600315T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL18714194.0T 2017-03-21 2018-03-21 Nowe terapeutyczne zastosowanie ligandów h3 PL3600315T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305309.1A EP3378477A1 (fr) 2017-03-21 2017-03-21 Nouvelles utilisations thérapeutiques de ligands h3
PCT/EP2018/057215 WO2018172432A1 (fr) 2017-03-21 2018-03-21 Nouvelle utilisation thérapeutique de ligands h3

Publications (1)

Publication Number Publication Date
PL3600315T3 true PL3600315T3 (pl) 2024-03-18

Family

ID=58464477

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18714194.0T PL3600315T3 (pl) 2017-03-21 2018-03-21 Nowe terapeutyczne zastosowanie ligandów h3

Country Status (25)

Country Link
US (1) US11179329B2 (fr)
EP (2) EP3378477A1 (fr)
JP (2) JP7634987B2 (fr)
KR (1) KR20190125354A (fr)
CN (1) CN110891570A (fr)
AU (1) AU2018238411B2 (fr)
BR (1) BR112019019633A2 (fr)
CA (1) CA3056710A1 (fr)
DK (1) DK3600315T3 (fr)
ES (1) ES2971063T3 (fr)
FI (1) FI3600315T3 (fr)
HR (1) HRP20231568T1 (fr)
HU (1) HUE064403T2 (fr)
IL (1) IL269424B2 (fr)
LT (1) LT3600315T (fr)
MA (1) MA48983A (fr)
MX (1) MX388589B (fr)
PL (1) PL3600315T3 (fr)
PT (1) PT3600315T (fr)
RS (1) RS64910B1 (fr)
RU (1) RU2757996C2 (fr)
SI (1) SI3600315T1 (fr)
SM (1) SMT202300460T1 (fr)
WO (1) WO2018172432A1 (fr)
ZA (1) ZA201906238B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3378858A1 (fr) * 2017-03-21 2018-09-26 Bioprojet Tétrahydrate de ligand h3, son procédé de préparation et compositions pharmaceutiques le comprenant
PT3598975T (pt) 2018-07-27 2020-12-21 Bioprojet Soc Civ Novas combinações de um antagonista h3 e um inibidor da re-assimilação da noradrenalina, e suas utilizações terapêuticas
WO2020092604A1 (fr) * 2018-10-30 2020-05-07 Concert Pharmaceuticals, Inc. Pitolisant deutéré
EP3976600B1 (fr) * 2019-06-03 2026-05-20 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Sels crystallins non-hygroscopiques d'un composé pyrazole, compositions pharmaceitiques les contenant et leur utilisation
CN116675654B (zh) * 2022-02-22 2025-06-13 上海云晟研新生物科技有限公司 卡利拉嗪药用盐及其晶型、药物组合物、制备方法和用途
CN122374013A (zh) * 2023-10-16 2026-07-10 生物计划制药公司 替洛利生的新制剂和使用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2579596B1 (fr) * 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
FR2660862B1 (fr) * 1990-04-13 1994-09-23 Bioprojet Soc Civ Application therapeutique de derives de l'histamine, nouveau derive de l'histamine et utilisation de ces derives pour la preparation de medicaments.
EP0982300A3 (fr) * 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines comme antagonistes du recepteur histamine H3 et leur application thérapeutique
MXPA04009961A (es) 2002-04-12 2004-12-13 Pfizer Compuestos de imidazol como agentes anti-inflamatorios y analgesicos.
JP5005351B2 (ja) 2003-12-11 2012-08-22 アボット・ラボラトリーズ Ｈｉｖプロテアーゼ阻害性化合物
EP1717235A3 (fr) 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines et leur utilisation comme ligands du récepteur histaminique H3
WO2009030716A1 (fr) * 2007-09-06 2009-03-12 Glaxo Group Limited Dérivé de pipérazine présentant une affinité pour le récepteur h3 de l'histamine
WO2009154562A1 (fr) 2008-06-20 2009-12-23 Astrazeneca Ab Composition pharmaceutique comprenant un composé 4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yle pour la modulation de l'activité des bêta-2-adrénorécepteurs
ME02320B (me) * 2010-09-02 2016-06-20 Suven Life Sciences Ltd Heterociklička jedinjenja kao ligandi histamin h3 receptora
US9212180B2 (en) * 2013-06-12 2015-12-15 The Regents Of The University Of Michigan Menin-MLL inhibitors and methods of use thereof
EP3378858A1 (fr) 2017-03-21 2018-09-26 Bioprojet Tétrahydrate de ligand h3, son procédé de préparation et compositions pharmaceutiques le comprenant

Also Published As

Publication number Publication date
AU2018238411B2 (en) 2023-07-06
RU2757996C2 (ru) 2021-10-25
MX388589B (es) 2025-03-20
RS64910B1 (sr) 2023-12-29
HRP20231568T1 (hr) 2024-03-15
AU2018238411A1 (en) 2019-10-10
FI3600315T3 (fi) 2023-12-11
JP7634987B2 (ja) 2025-02-25
IL269424B1 (en) 2023-03-01
ZA201906238B (en) 2020-09-30
EP3378477A1 (fr) 2018-09-26
SI3600315T1 (sl) 2024-02-29
HUE064403T2 (hu) 2024-03-28
EP3600315A1 (fr) 2020-02-05
MA48983A (fr) 2021-04-21
NZ757456A (en) 2026-02-27
LT3600315T (lt) 2023-12-27
WO2018172432A1 (fr) 2018-09-27
MX2019011183A (es) 2020-02-05
SMT202300460T1 (it) 2024-01-10
JP2020511551A (ja) 2020-04-16
IL269424B2 (en) 2023-07-01
ES2971063T3 (es) 2024-06-03
US11179329B2 (en) 2021-11-23
RU2019129447A (ru) 2021-03-18
CN110891570A (zh) 2020-03-17
IL269424A (en) 2019-11-28
KR20190125354A (ko) 2019-11-06
DK3600315T3 (da) 2023-12-11
BR112019019633A2 (pt) 2020-04-14
CA3056710A1 (fr) 2018-09-27
JP2023001210A (ja) 2023-01-04
RU2019129447A3 (fr) 2021-03-18
PT3600315T (pt) 2023-12-11
US20200093738A1 (en) 2020-03-26
EP3600315B1 (fr) 2023-09-06

Similar Documents

Publication Publication Date Title
ZA202006746B (en) Methods of treatment
ZA201905677B (en) Glycan-interacting compounds and methods of use
GB201709435D0 (en) Medical devices
GB201804514D0 (en) Treatment of pyroptosis
ZA201906238B (en) New therapeutical use of h3-ligands
GB201715194D0 (en) Compounds and their therapeutic use
IL265955A (en) Therapeutic compounds and methods of using them
PT3661491T (pt) 3-metilmetcatinona para uso no tratamento de um indivíduo sob uma intervenção psicoterapêutica
IL285882A (en) Medicinal uses for l–4–chlorokynurenine
GB201608797D0 (en) Therapeutic use
ZA201802134B (en) Therapeutic compounds and methods of use thereof
GB201804515D0 (en) Treatment of necroptosis
GB201700526D0 (en) Therapeutic use
ZA202105399B (en) Use of spiropidion
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
GB201705686D0 (en) Novel compounds and therapeutic uses thereof
GB2568495B (en) Methods of coating medical devices
GB201707500D0 (en) New therapy
SG11202105136WA (en) Application of chidamide
GB201705684D0 (en) Novel compounds and therapeutic uses thereof
GB201810835D0 (en) Methods of use
GB2558788B (en) New therapeutic uses
GB201721386D0 (en) Chrondogy of time-wave
GB201707076D0 (en) Novel compounds and therapeutic uses thereof
GB201705685D0 (en) Novel compounds and therapeutic uses thereof